ALPS · 2014-12-30 成立 · 规模、费率、NAV、资金流、完整持仓和风险收益使用各自可追溯公开源。
| 日期 | 估算净流 | 申购 / 销售 | 赎回 | 净资产 | 口径 |
|---|---|---|---|---|---|
| 2026-07-31 | +$3.5M | — | — | $200.2M | 每日估算 |
| 2026-07-28 | -$15.8M | — | — | $190.4M | 每日估算 |
| 2026-07-27 | +$15.2M | — | — | $203.9M | 每日估算 |
| 2026-07-26 | -$11.7M | — | — | $190.4M | 每日估算 |
| 2026-02-28 | -$1.3M | $3.8M | $5.1M | $138.0M |
| 持仓 | 资产类别 | 数量 | 市值 | 权重 |
|---|---|---|---|---|
Kymera Therapeutics, Inc. Kymera Therapeutics, Inc. | EC | 70,365 | $6.4M | 4.66% |
Celcuity, Inc. Celcuity, Inc. | EC | 41,241 | $4.6M | 3.34% |
Alkermes PLC Alkermes PLC | EC | 147,168 | $4.4M | 3.21% |
CG oncology, Inc. CG oncology, Inc. | EC |
行情与风险截至 2026-07-30；NAV 的发布时间可能和交易所收盘错位。完整持仓是延迟监管披露，不代表当前盘中组合。
已使用：nasdaq_etf_screener、nasdaq_etf_summary、yahoo_chart、yahoo_quote_summary、sec_nport。缺口标记：nav_timestamp_unverified、category_reclassified_by_current_taxonomy。
| SEC 月度 |
| 2026-01-31 | +$10.5M | $11.8M | $1.2M | — | SEC 月度 |
| 2025-12-31 | +$20.2M | $20.2M | $0 | — | SEC 月度 |
| 71,897 |
| $4.2M |
| 3.06% |
Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. | EC | 45,804 | $4.2M | 3.06% |
Amicus Therapeutics, Inc. Amicus Therapeutics, Inc. | EC | 274,988 | $4.0M | 2.86% |
ACADIA Pharmaceuticals, Inc. ACADIA Pharmaceuticals, Inc. | EC | 150,789 | $3.7M | 2.68% |
Newamsterdam Pharma Co. NV Newamsterdam Pharma Co. NV | EC | 101,063 | $3.6M | 2.60% |
Crinetics Pharmaceuticals, Inc. Crinetics Pharmaceuticals, Inc. | EC | 84,576 | $3.5M | 2.52% |
Apogee Therapeutics, Inc. Apogee Therapeutics, Inc. | EC | 48,872 | $3.4M | 2.48% |
Viking Therapeutics, Inc. Viking Therapeutics, Inc. | EC | 100,746 | $3.4M | 2.47% |
Structure Therapeutics, Inc. Structure Therapeutics, Inc. | EC | 54,083 | $3.4M | 2.47% |
Xenon Pharmaceuticals, Inc. Xenon Pharmaceuticals, Inc. | EC | 68,873 | $3.0M | 2.16% |
Spyre Therapeutics, Inc. Spyre Therapeutics, Inc. | EC | 69,157 | $3.0M | 2.15% |
Edgewise Therapeutics, Inc. Edgewise Therapeutics, Inc. | EC | 94,360 | $2.9M | 2.08% |
Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. | EC | 37,835 | $2.9M | 2.07% |
Denali Therapeutics, Inc. Denali Therapeutics, Inc. | EC | 131,033 | $2.8M | 2.01% |
Ideaya Biosciences, Inc. Ideaya Biosciences, Inc. | EC | 78,135 | $2.5M | 1.82% |
Travere Therapeutics, Inc. Travere Therapeutics, Inc. | EC | 79,744 | $2.4M | 1.72% |
Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals, Inc. | EC | 112,768 | $2.4M | 1.71% |
Vera Therapeutics, Inc. Vera Therapeutics, Inc. | EC | 56,977 | $2.3M | 1.68% |
Disc Medicine, Inc. Disc Medicine, Inc. | EC | 33,646 | $2.2M | 1.62% |
Dianthus Therapeutics, Inc. Dianthus Therapeutics, Inc. | EC | 38,214 | $2.1M | 1.53% |
Mineralys Therapeutics, Inc. Mineralys Therapeutics, Inc. | EC | 70,537 | $2.1M | 1.50% |
Galapagos NV Galapagos NV | EC | 58,387 | $2.0M | 1.42% |
Maze Therapeutics, Inc. Maze Therapeutics, Inc. | EC | 42,889 | $2.0M | 1.42% |
Zai Lab, Ltd. Zai Lab, Ltd. | EC | 99,972 | $1.9M | 1.39% |
Stoke Therapeutics, Inc. Stoke Therapeutics, Inc. | EC | 50,908 | $1.9M | 1.34% |
Nuvation Bio, Inc. Nuvation Bio, Inc. | EC | 305,559 | $1.8M | 1.31% |
Celldex Therapeutics, Inc. Celldex Therapeutics, Inc. | EC | 59,226 | $1.8M | 1.29% |
Olema Pharmaceuticals, Inc. Olema Pharmaceuticals, Inc. | EC | 70,109 | $1.7M | 1.23% |
Pharvaris NV Pharvaris NV | EC | 57,094 | $1.6M | 1.17% |
Vericel Corp. Vericel Corp. | EC | 45,076 | $1.6M | 1.17% |
Relay Therapeutics, Inc. Relay Therapeutics, Inc. | EC | 154,480 | $1.6M | 1.15% |
Tyra Biosciences, Inc. Tyra Biosciences, Inc. | EC | 47,570 | $1.6M | 1.15% |
Agios Pharmaceuticals, Inc. Agios Pharmaceuticals, Inc. | EC | 51,973 | $1.6M | 1.14% |
Sarepta Therapeutics, Inc. Sarepta Therapeutics, Inc. | EC | 93,395 | $1.6M | 1.13% |
Oculis Holding AG Oculis Holding AG | EC | 50,955 | $1.5M | 1.09% |
Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals, Inc. | EC | 97,879 | $1.5M | 1.08% |
Oruka Therapeutics, Inc. Oruka Therapeutics, Inc. | EC | 43,144 | $1.5M | 1.08% |
Novavax, Inc. Novavax, Inc. | EC | 144,833 | $1.5M | 1.06% |
Immunocore Holdings PLC Immunocore Holdings PLC | EC | 45,035 | $1.5M | 1.05% |
Sionna Therapeutics, Inc. Sionna Therapeutics, Inc. | EC | 39,776 | $1.5M | 1.05% |
Palvella Therapeutics, Inc. Palvella Therapeutics, Inc. | EC | 10,552 | $1.4M | 1.03% |
MBX Biosciences, Inc. MBX Biosciences, Inc. | EC | 40,022 | $1.3M | 0.94% |
Zenas Biopharma, Inc. Zenas Biopharma, Inc. | EC | 47,842 | $1.3M | 0.91% |
Immatics NV Immatics NV | EC | 119,488 | $1.2M | 0.90% |
Rapport Therapeutics, Inc. Rapport Therapeutics, Inc. | EC | 42,477 | $1.2M | 0.89% |
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc. | EC | 66,564 | $1.2M | 0.88% |
Taysha Gene Therapies, Inc. Taysha Gene Therapies, Inc. | EC | 244,138 | $1.1M | 0.80% |
MoonLake Immunotherapeutics MoonLake Immunotherapeutics | EC | 63,143 | $1.1M | 0.80% |
Day One Biopharmaceuticals, Inc. Day One Biopharmaceuticals, Inc. | EC | 91,514 | $970,048 | 0.70% |
Geron Corp. Geron Corp. | EC | 568,951 | $955,838 | 0.69% |
MannKind Corp. MannKind Corp. | EC | 273,687 | $897,693 | 0.65% |
Compass Therapeutics, Inc. Compass Therapeutics, Inc. | EC | 158,523 | $895,655 | 0.65% |
ArriVent Biopharma, Inc. ArriVent Biopharma, Inc. | EC | 36,792 | $845,112 | 0.61% |
Theravance Biopharma, Inc. Theravance Biopharma, Inc. | EC | 45,164 | $824,243 | 0.60% |
Bicara Therapeutics, Inc. Bicara Therapeutics, Inc. | EC | 48,826 | $819,300 | 0.59% |
ARS Pharmaceuticals, Inc. ARS Pharmaceuticals, Inc. | EC | 88,100 | $817,568 | 0.59% |
Xencor, Inc. Xencor, Inc. | EC | 63,648 | $812,785 | 0.59% |
KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc. | EC | 45,051 | $733,430 | 0.53% |
Kura Oncology, Inc. Kura Oncology, Inc. | EC | 77,558 | $677,081 | 0.49% |
Rigel Pharmaceuticals, Inc. Rigel Pharmaceuticals, Inc. | EC | 16,180 | $562,093 | 0.41% |
Alto Neuroscience, Inc. Alto Neuroscience, Inc. | EC | 27,688 | $545,177 | 0.39% |
Design Therapeutics, Inc. Design Therapeutics, Inc. | EC | 50,771 | $530,049 | 0.38% |
Vanda Pharmaceuticals, Inc. Vanda Pharmaceuticals, Inc. | EC | 52,672 | $469,308 | 0.34% |
Fulgent Genetics, Inc. Fulgent Genetics, Inc. | EC | 27,554 | $422,403 | 0.31% |
REGENXBIO, Inc. REGENXBIO, Inc. | EC | 45,118 | $407,867 | 0.30% |
Altimmune, Inc. Altimmune, Inc. | EC | 92,999 | $400,826 | 0.29% |
Tectonic Therapeutic, Inc. Tectonic Therapeutic, Inc. | EC | 16,682 | $391,193 | 0.28% |
Zura Bio, Ltd. Zura Bio, Ltd. | EC | 57,952 | $383,642 | 0.28% |
Upstream Bio, Inc. Upstream Bio, Inc. | EC | 48,162 | $369,884 | 0.27% |
Anavex Life Sciences Corp. Anavex Life Sciences Corp. | EC | 79,635 | $352,783 | 0.26% |
Forte Biosciences, Inc. Forte Biosciences, Inc. | EC | 11,166 | $337,437 | 0.24% |
Atea Pharmaceuticals, Inc. Atea Pharmaceuticals, Inc. | EC | 69,634 | $325,887 | 0.24% |
Neurogene, Inc. Neurogene, Inc. | EC | 13,806 | $324,303 | 0.23% |
Akebia Therapeutics, Inc. Akebia Therapeutics, Inc. | EC | 236,514 | $309,833 | 0.22% |
Protara Therapeutics, Inc. Protara Therapeutics, Inc. | EC | 46,015 | $292,655 | 0.21% |
Delcath Systems, Inc. Delcath Systems, Inc. | EC | 31,472 | $280,101 | 0.20% |
Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. | EC | 96,567 | $277,147 | 0.20% |
Rezolute, Inc. Rezolute, Inc. | EC | 82,647 | $265,297 | 0.19% |
Candel Therapeutics, Inc. Candel Therapeutics, Inc. | EC | 48,929 | $256,877 | 0.19% |
Bicycle Therapeutics PLC Bicycle Therapeutics PLC | EC | 44,503 | $255,002 | 0.18% |
Aardvark Therapeutics, Inc. Aardvark Therapeutics, Inc. | EC | 19,407 | $242,393 | 0.18% |
Arcturus Therapeutics Holdings, Inc. Arcturus Therapeutics Holdings, Inc. | EC | 25,324 | $208,417 | 0.15% |
State Street Institutional Treasury Plus Money Market Fund State Street Institutional Treasury Plus Money Market Fund | STIV | 50,717 | $50,717 | 0.04% |
2600057D Novo Nordisk A/S | DE | 1,233 | $0 | 0.00% |
2334482D AstraZeneca PLC | DE | 36,586 | $0 | 0.00% |
1835589D Chinook Therapeutics, Inc. | DE | 20,700 | $0 | 0.00% |
SECLEND SECURITIES LENDING - GENERAL | STIV | 0 | $0 | 0.00% |
OmniAb, Inc. OmniAb, Inc. | DE | 3,653 | $0 | 0.00% |
OmniAb, Inc. OmniAb, Inc. | DE | 3,653 | $0 | 0.00% |